Efficacy of Tandem High-Dose Chemotherapy and Autologous Stem Cell Rescue in Patients Over 1 Year of Age with Stage 4 Neuroblastoma: The Korean Society of Pediatric Hematology-Oncology Experience Over 6 Years (2000-2005).
10.3346/jkms.2010.25.5.691
- Author:
Ki Woong SUNG
1
;
Hyo Seop AHN
;
Bin CHO
;
Yong Mook CHOI
;
Nack Gyun CHUNG
;
Tai Ju HWANG
;
Ho Joon IM
;
Dae Chul JEONG
;
Hyoung Jin KANG
;
Hong Hoe KOO
;
Hoon KOOK
;
Hack Ki KIM
;
Chuhl Joo LYU
;
Jong Jin SEO
;
Hee Young SHIN
;
Keon Hee YOO
;
Sung Chul WON
;
Kun Soo LEE
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Controlled Clinical Trial ; Original Article ; Multicenter Study
- Keywords:
Neuroblastoma;
High-dose Chemotherapy;
Transplantation, Autologous
- MeSH:
Adolescent;
Child;
Child, Preschool;
Combined Modality Therapy/mortality;
Drug Therapy/*mortality;
Female;
Humans;
Infant;
Korea/epidemiology;
Longitudinal Studies;
Male;
Neuroblastoma/*mortality/*therapy;
Prevalence;
Risk Assessment/methods;
Risk Factors;
Stem Cell Transplantation/*mortality;
Survival Analysis;
Survival Rate;
Treatment Outcome
- From:Journal of Korean Medical Science
2010;25(5):691-697
- CountryRepublic of Korea
- Language:English
-
Abstract:
The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival+/-95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2+/-12.4% vs. 31.3+/-11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.
